絞り込み

17698

広告

A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).

著者 Fujiwara H , Ushijima K , Nagao S , Takei Y , Shimada M , Takano M , Yoshino K , Kawano Y , Hirashima Y , Nagase S , Nishio S , Nishikawa T , Ito K , Shoji T , Kimura E , Takano T , Sugiyama T , Kigawa J , Fujiwara K , Suzuki M
Int J Clin Oncol.2019 May 24 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (24view , 0users)

Full Text Sources

Medical

Miscellaneous

To compare the efficacy, safety, and tolerability profiles of pegylated liposomal doxorubicin and carboplatin (PLDC) with those of gemcitabine and carboplatin (GC) for the treatment of patients with platinum-sensitive recurrent ovarian cancer.
PMID: 31127479 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード